| 2025-10-07 |
详情>>
内部人交易：
Klichinsky Michael共交易2笔
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-0.46美元,归母净利润-1904万美元,同比去年增长36.83%
|
| 2025-07-07 |
股东大会：
将于2025-08-05召开股东大会
会议内容 ▼▲
- 1.To adopt and approve an amendment to our Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued shares of common stock at a ratio within the range of not less than 1-for-10 and not greater than 1-for-50, with the exact ratio within such range and the implementation and timing of such reverse stock split to be determined at the sole discretion of our Board of Directors, without further approval or authorization of our stockholders (the “Reverse Split Proposal”).
2.To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary to permit further solicitation of proxies in the event that there are insufficient votes for the adoption and approval of the Reverse Split Proposal.
|
| 2025-07-07 |
股东大会：
将于2025-08-05召开股东大会
会议内容 ▼▲
- 1.To adopt and approve an amendment to our Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued shares of common stock at a ratio within the range of not less than 1-for-10 and not greater than 1-for-50, with the exact ratio within such range and the implementation and timing of such reverse stock split to be determined at the sole discretion of our Board of Directors, without further approval or authorization of our stockholders (the “Reverse Split Proposal”).
2.To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary to permit further solicitation of proxies in the event that there are insufficient votes for the adoption and approval of the Reverse Split Proposal.
|
| 2025-06-23 |
复牌提示：
2025-06-23 07:25:00 停牌，复牌日期 2025-06-23 08:00:00
|
| 2025-05-13 |
详情>>
股本变动：
变动后总股本4178.81万股
变动原因 ▼▲
- 原因：
- From December 31, 2024 to March 31, 2025
Exercise of stock options
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.22美元,归母净利润-926.6万美元,同比去年增长51.18%
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-1.46美元,归母净利润-6047.7万美元,同比去年增长30.39%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.04美元,归母净利润-4284.2万美元,同比去年增长35.01%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.73美元,归母净利润-3014万美元,同比去年增长32.30%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.46美元,归母净利润-1897.8万美元,同比去年增长22.99%
|
| 2024-04-29 |
股东大会：
将于2024-06-13召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors, John Hohneker, M.D. and Michael Torok, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders;
2.To hold an advisory vote on named executive officer compensation;
3.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
4.To transact any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-04-29 |
股东大会：
将于2024-06-13召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors, John Hohneker, M.D. and Michael Torok, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders;
2.To hold an advisory vote on named executive officer compensation;
3.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
4.To transact any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-04-01 |
详情>>
业绩披露：
2023年年报每股收益-2.59美元,归母净利润-8687.9万美元,同比去年增长-41.9%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.11美元,归母净利润-6592.1万美元,同比去年增长-48.18%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-1.67美元,归母净利润-4451.8万美元,同比去年增长-70.18%
|
| 2023-05-11 |
详情>>
业绩披露：
2023年一季报每股收益-1.93美元,归母净利润-2464.2万美元,同比去年增长-117.84%
|
| 2023-04-28 |
股东大会：
将于2023-06-06召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors, Regina Hodits, Ph.D. and Bjorn Odlander, M.D., Ph.D., each to serve until the 2026 annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To hold an advisory vote on named executive officer compensation;
3.To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 350,000,000;
4.To approve an amendment and restatement of the Carisma Therapeutics Inc. Amended and Restated 2014 Stock Incentive Plan, or the 2014 Plan;
5.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
6.To transact any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2023-04-28 |
股东大会：
将于2023-06-06召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors, Regina Hodits, Ph.D. and Bjorn Odlander, M.D., Ph.D., each to serve until the 2026 annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To hold an advisory vote on named executive officer compensation;
3.To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 350,000,000;
4.To approve an amendment and restatement of the Carisma Therapeutics Inc. Amended and Restated 2014 Stock Incentive Plan, or the 2014 Plan;
5.To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
6.To transact any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2023-03-02 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2022-04-28 |
股东大会：
将于2022-06-22召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors to our board of directors, or our Board, to serve until the 2025 annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To approve an amendment to our Restated Certificate of Incorporation, to effect a reverse stock split of our common stock at a ratio in the range of 1:5 to 1:10, and a proportionate reduction in the number of authorized shares of common stock, such ratio and the implementation and timing of the reverse stock split to be determined in the discretion of our board of directors;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
4.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement;
5.To transact such other business as may properly come before the 2022 Annual Meeting or any adjournment or postponement thereof.
|
| 2022-04-28 |
股东大会：
将于2022-06-22召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors to our board of directors, or our Board, to serve until the 2025 annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To approve an amendment to our Restated Certificate of Incorporation, to effect a reverse stock split of our common stock at a ratio in the range of 1:5 to 1:10, and a proportionate reduction in the number of authorized shares of common stock, such ratio and the implementation and timing of the reverse stock split to be determined in the discretion of our board of directors;
3.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
4.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement;
5.To transact such other business as may properly come before the 2022 Annual Meeting or any adjournment or postponement thereof.
|
| 2021-03-25 |
股东大会：
将于2021-05-03召开股东大会
会议内容 ▼▲
- 1.To elect two class I directors to our board of directors, or our Board, to serve until the 2024 annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000;
3.To approve an amendment to our 2014 Stock Incentive Plan, or the 2014 Incentive Plan, to increase the number of shares of common stock reserved for issuance under the 2014 Incentive Plan by 12,000,000 shares of common stock;
4.To approve an amendment to our 2014 Employee Stock Purchase Plan, or the 2014 ESPP, to increase the number of shares of common stock reserved for issuance under the 2014 ESPP by 2,300,000 shares of common stock;
5.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
6.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement;
7.To transact such other business as may properly come before the 2021 Annual Meeting or any adjournment or postponement thereof.
|
| 2021-03-25 |
股东大会：
将于2021-05-03召开股东大会
会议内容 ▼▲
- 1.To elect two class I directors to our board of directors, or our Board, to serve until the 2024 annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000;
3.To approve an amendment to our 2014 Stock Incentive Plan, or the 2014 Incentive Plan, to increase the number of shares of common stock reserved for issuance under the 2014 Incentive Plan by 12,000,000 shares of common stock;
4.To approve an amendment to our 2014 Employee Stock Purchase Plan, or the 2014 ESPP, to increase the number of shares of common stock reserved for issuance under the 2014 ESPP by 2,300,000 shares of common stock;
5.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
6.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement;
7.To transact such other business as may properly come before the 2021 Annual Meeting or any adjournment or postponement thereof.
|
| 2020-03-30 |
股东大会：
将于2020-05-06召开股东大会
会议内容 ▼▲
- 1.To elect one class III director to our board of directors, to serve until the 2023 annual meeting of stockholders and until her successor has been duly elected and qualified;
2.To approve an amendment to our Restated Certificate of Incorporation, to effect a reverse stock split of our common stock at a ratio in the range of 1:3 to 1:10, such ratio to be determined in the discretion of our board of directors;
3.To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020;
4.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement;
5.To approve, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of our named executive officers;
6.To transact such other business as may properly come before the 2020 Annual Meeting or any adjournment or postponement thereof.
|
| 2020-03-30 |
股东大会：
将于2020-05-06召开股东大会
会议内容 ▼▲
- 1.To elect one class III director to our board of directors, to serve until the 2023 annual meeting of stockholders and until her successor has been duly elected and qualified;
2.To approve an amendment to our Restated Certificate of Incorporation, to effect a reverse stock split of our common stock at a ratio in the range of 1:3 to 1:10, such ratio to be determined in the discretion of our board of directors;
3.To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020;
4.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement;
5.To approve, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of our named executive officers;
6.To transact such other business as may properly come before the 2020 Annual Meeting or any adjournment or postponement thereof.
|
| 2019-04-30 |
股东大会：
将于2019-06-19召开股东大会
会议内容 ▼▲
- 1.To elect two class II directors of our board of directors, each to serve until the 2022 annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To approve an amendment of our 2014 Stock Incentive Plan, or the 2014 Plan, to (i) increase the number of shares reserved for issuance under the 2014 Plan by 7,908,972 shares and (ii) eliminate the “evergreen” or automatic replenishment provision of the 2014 Plan pursuant to which the number of shares authorized for issuance under the 2014 Plan is automatically increased on an annual basis;
3.To ratify the selection of Ernst & Young LLP as Sesen Bio's independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.To transact such other business as may properly come before the 2019 Annual Meeting or any adjournment or postponement thereof.
|
| 2019-04-30 |
股东大会：
将于2019-06-19召开股东大会
会议内容 ▼▲
- 1.To elect two class II directors of our board of directors, each to serve until the 2022 annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To approve an amendment of our 2014 Stock Incentive Plan, or the 2014 Plan, to (i) increase the number of shares reserved for issuance under the 2014 Plan by 7,908,972 shares and (ii) eliminate the “evergreen” or automatic replenishment provision of the 2014 Plan pursuant to which the number of shares authorized for issuance under the 2014 Plan is automatically increased on an annual basis;
3.To ratify the selection of Ernst & Young LLP as Sesen Bio's independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.To transact such other business as may properly come before the 2019 Annual Meeting or any adjournment or postponement thereof.
|
| 2018-04-30 |
股东大会：
将于2018-06-12召开股东大会
会议内容 ▼▲
- 1.To elect two class I directors of our board of directors, each to serve until the 2021 annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the selection of Ernst & Young LLP as Eleven Biotherapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.To transact such other business as may properly come before the 2018 Annual Meeting or any adjournment or postponement thereof.
|
| 2018-04-30 |
股东大会：
将于2018-06-12召开股东大会
会议内容 ▼▲
- 1.To elect two class I directors of our board of directors, each to serve until the 2021 annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To ratify the selection of Ernst & Young LLP as Eleven Biotherapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.To transact such other business as may properly come before the 2018 Annual Meeting or any adjournment or postponement thereof.
|
| 2017-04-07 |
股东大会：
将于2017-05-19召开股东大会
会议内容 ▼▲
- 1. To elect three class III directors of our board of directors, each to serve until the 2020 annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2. To ratify the selection of Ernst & Young LLP as Eleven Biotherapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2017;
3. To transact such other business as may properly come before the 2017 Annual Meeting or any adjournment or postponement thereof.
|
| 2017-04-07 |
股东大会：
将于2017-05-19召开股东大会
会议内容 ▼▲
- 1. To elect three class III directors of our board of directors, each to serve until the 2020 annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2. To ratify the selection of Ernst & Young LLP as Eleven Biotherapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2017;
3. To transact such other business as may properly come before the 2017 Annual Meeting or any adjournment or postponement thereof.
|
| 2016-07-14 |
股东大会：
将于2016-08-15召开股东大会
会议内容 ▼▲
- 1. To consider and vote on a proposal (the “License Transaction Proposal”) to authorize the transactions contemplated by the License Agreement, dated as of June 10, 2016 (the “License Agreement”), by and between the Company, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., including the grant of the exclusive licenses thereunder (the “License Transaction”);
2. To approve one or more adjournments of the Special Meeting, if necessary or appropriate, to solicit additional proxies to approve the License Transaction Proposal;
3. To transact such other business as may properly come before the Special Meeting or any adjournment or postponement thereof.
|
| 2016-07-14 |
股东大会：
将于2016-08-15召开股东大会
会议内容 ▼▲
- 1. To consider and vote on a proposal (the “License Transaction Proposal”) to authorize the transactions contemplated by the License Agreement, dated as of June 10, 2016 (the “License Agreement”), by and between the Company, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., including the grant of the exclusive licenses thereunder (the “License Transaction”);
2. To approve one or more adjournments of the Special Meeting, if necessary or appropriate, to solicit additional proxies to approve the License Transaction Proposal;
3. To transact such other business as may properly come before the Special Meeting or any adjournment or postponement thereof.
|
| 2016-04-29 |
股东大会：
将于2016-06-08召开股东大会
会议内容 ▼▲
- 1. To elect three class II directors of our board of directors to serve until the annual meeting of stockholders to be held in 2019 or until their respective successors have been duly elected and qualified;
2. To ratify the selection of Ernst & Young LLP as Eleven Biotherapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2016;
3. To transact such other business as may properly come before the 2016 Annual Meeting or any adjournment or postponement thereof.
|
| 2016-04-29 |
股东大会：
将于2016-06-08召开股东大会
会议内容 ▼▲
- 1. To elect three class II directors of our board of directors to serve until the annual meeting of stockholders to be held in 2019 or until their respective successors have been duly elected and qualified;
2. To ratify the selection of Ernst & Young LLP as Eleven Biotherapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2016;
3. To transact such other business as may properly come before the 2016 Annual Meeting or any adjournment or postponement thereof.
|